ClinicalThought

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer: Education and Resources for the Multidisciplinary Team

Review the latest evidence-based strategies for HR-positive/HER2-negative early breast cancer with an on-demand webcast, downloadable slides from a live presentation series, a series of expert commentaries, a downloadable patient resource, and a patient’s story podcast.

Julia LaBarbera, MSN, RN, AGACNP-BC

Joyce O'Shaughnessy, MD

ClinicalThought

How Risk of Recurrence in HR-Positive/HER2-Negative Early Breast Cancer Impacts Therapeutic Choices

View ClinicalThought

An expert discusses the impact of risk of recurrence on treatment selection for patients with early‑stage hormone receptor–positive/HER2‑negative breast cancer.

Joyce O'Shaughnessy, MD Released: November 14, 2022

ClinicalThought

Optimizing Patient Outcomes and Quality of Life With Adjuvant Abemaciclib in HR+/HER2- Early Breast Cancer Through Adverse Event Management

View ClinicalThought

Read about how managing the adverse events associated with adjuvant abemaciclib can affect patients with HR-positive/HER2 negative early breast cancer.

Julia LaBarbera, MSN, RN, AGACNP-BC Released: January 31, 2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer: Education and Resources for the Multidisciplinary Team

How Risk of Recurrence in HR-Positive/HER2-Negative Early Breast Cancer Impacts Therapeutic Choices

Optimizing Patient Outcomes and Quality of Life With Adjuvant Abemaciclib in HR+/HER2- Early Breast Cancer Through Adverse Event Management

Leaving the CCO site